<DOC>
	<DOCNO>NCT01313689</DOCNO>
	<brief_summary>The purpose study confirm clinical benefit observe pivotal registration study , Hx-CD20-406 . The Committee Medicinal Products Human Use ( CHMP ) require randomize study conduct CLL patient bulky fludarabine-refractory disease specific obligation grant conditional approval ARZERRAâ„¢ European Union ( EU ) . This study compare ofatumumab physician ' choice therapy .</brief_summary>
	<brief_title>Ofatumumab v Physician 's Choice Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>Patients CLL refractory fludarabine treatment option poor prognosis . There continue need new therapy CLL patient , demonstrate limited response substantial toxicity exist therapy . This support lack consensus around standard care treatment CLL patient bulky fludarabine-refractory disease . The objective study confirm response rate disease control refractory set control trial compare ofatumumab physician ' choice therapy fludarabine-refractory , bulky lymphadenopathy patient . After 24 week treatment ofatumumab , patient randomize either extended ofatumumab treatment observation . Patients physician ' choice arm option receive ofatumumab experience progressive disease .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults document diagnosis active CLL require treatment Bulky lymphadenopathy , define least 1 lymph node &gt; 5 cm Must refractory fludarabine treatment Age 18 yr old At least 2 prior therapy CLL Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Signed write informed consent Prior allogeneic stem cell transplant time , autologous stem cell transplant within 6 month Treatment unapproved drug substance experimental therapy within 4 week , currently participate another interventional clinical study CLL transformation , prolymphocytic leukemia , central nervous system ( CNS ) involvement CLL Active autoimmune hemolytic anemia ( AIHA ) require treatment except associate progressive disease require antiCLL treatment Chronic current active infectious disease require systemic antibiotic , antifungal , antiviral treatment Human immunodeficiency virus ( HIV ) positive Significant concurrent , uncontrolled medical condition Other past current malignancy ( exception basal cell carcinoma skin situ carcinoma cervix breast ) unless tumor successfully treat curative intent least 2 year prior trial entry Nonprotocol corticosteroid usage except maintenance dose correspond less equal 10 mg prednisone Abnormal lab value : Creatinine &gt; 2.0 time upper normal limit ( unless normal creatinine clearance ) , total bilirubin &gt; 2.0 time upper normal limit ( unless due liver involvement CLL due Gilbert 's syndrome ) , alanine transaminase ( ALT ) &gt; 2.5 time upper normal limit ( unless due liver involvement CLL ) Known suspect hypersensitivity ofatumumab Lactating pregnant woman female patient childbearing potential ( male patient partner ) willing use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Refractory</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Oncology</keyword>
	<keyword>Ofatumumab</keyword>
	<keyword>Efficacy</keyword>
</DOC>